1109230-25-2

Basic information

• Product Name: 5-BroMo-3,4-dihydroisoquinolin-1(2H)-one
• Synonyms: 5-BroMo-3,4-dihydroisoquinolin-1(2H)-one;4-dihydroisoquinolin-1(2H)-one;5-Bromo-3,4-dihydro-2H-isoquinolin-1-one;5-bromo-3,4-dihydro-1(2H)-Isoquinolinone;5-Bromo-3,4-dihydroisoquinolin-1(2H)
• CAS NO: 1109230-25-2
• Molecular Formula: C₉H₈BrNO
• Molecular Weight: 226.06992
• Mol File: 1109230-25-2.mol
• Article Data: 19

Chemical Properties

• Melting Point: 180-183℃
• Boiling Point: 453.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.559
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.34±0.20(Predicted)
• CAS DataBase Reference: 5-BroMo-3,4-dihydroisoquinolin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMo-3,4-dihydroisoquinolin-1(2H)-one(1109230-25-2)
• EPA Substance Registry System: 5-BroMo-3,4-dihydroisoquinolin-1(2H)-one(1109230-25-2)

Safety Data

• Hazardous Substances Data: 1109230-25-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-3,4-dihydroisoquinolin-1(2H)-one is a chemical compound with the molecular formula C9H9BrNO. It is a heterocyclic compound that contains a bromine atom and a carbonyl group. 5-BroMo-3,4-dihydroisoquinolin-1(2H)-one has potential applications in medicinal chemistry and drug discovery, as it can serve as a building block for the synthesis of various biologically active molecules. Additionally, it may have use in the field of organic synthesis, where it can be employed as a versatile intermediate for the preparation of other complex chemical compounds. Further research and development of this chemical may lead to its use in various industrial and pharmaceutical applications.

Upstream product

• 75-75-2 methanesulfonic acid 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 140202-11-5 ethyl <2-(2-bromophenyl)ethyl>carbamate 
• 65185-58-2 2-(2-bromophenyl)ethanamine 
• 305447-65-8 methyl 4-(bromophen)ethylcarbamate 
• 1109230-24-1 methyl 2-(2-bromophenyl)ethylcarbamate 

Downstream Products

• 1109230-26-3 5-bromo-2-[1-(4-fluorophenyl)ethyl]-3,4-dihydroisoquinolin-1(2H)-one 
• 1309955-25-6 2-(4-chlorobutyl)-3,4-dihydro-5-phenylisoquinolin-1(2H)-one 
• 1309955-35-8 USC-N₄₀₁ 
• 1309955-15-4 3,4-dihydro-5-phenylisoquinolin-1(2H)-one 
• 190777-77-6 5-bromo-1,2-dihydroisoquinolin-1-one 
• 1100509-38-3 5-bromo-2-methyl-3,4-dihydroisoquinoline-1(2H)-one 
• 81237-69-6 5-bromo-1,2,3,4-tetrahydro-isoquinoline 
• 93258-88-9 methyl 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxylate 
• 1131222-53-1 2-allyl-5-bromo-3,4-dihydroisoquinolin-1(2H)-one 
• 1131215-88-7 4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-5-yl)benzonitrile hydrochloride 
• 1367905-79-0 5-bromo-2-methyl-2H-isoquinolin-1-one 
• 1109230-29-6 N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({1-[3-(trifluoromethyl)phenyl]cyclopropyl}amino)propyl]-2-[1-(4-fluorophenyl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide hydrochloride 
• 1109230-23-0 N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({1-[3-(trifluoromethyl)phenyl]cyclopropyl}amino)propyl]-2-[1-(4-fluorophenyl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide 
• 1109230-28-5 2-[1-(4-fluorophenyl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxylic acid 

Relevant articles and documents

New Series of Potent Allosteric Inhibitors of Deoxyhypusine Synthase

Deoxyhypusine synthase (DHPS) is the primary enzyme responsible for the hypusine modification and, thereby, activation of the eukaryotic translation initiation factor 5A (eIF5A), which is key in regulating the protein translation processes associated with tumor proliferation. Although DHPS inhibitors could be a promising therapeutic option for treating cancer, only a few studies reported druglike compounds with this inhibition property. Thus, in this work, we designed and synthesized a new chemical series possessing fused ring scaffolds designed from high-throughput screening hit compounds, discovering a 5,6-dihydrothieno[2,3-c]pyridine derivative (26d) with potent inhibitory activity; furthermore, the X-ray crystallographic analysis of the DHPS complex with 26d demonstrated a distinct allosteric binding mode compared to a previously reported inhibitor. These findings could be significantly useful in the functional analysis of conformational changes in DHPS as well as the structure-based design of allosteric inhibitors.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of adenosine or adenosine receptor related disorders.

Rational Design of Cell-Active Inhibitors of PARP10

Poly-ADP-ribose polymerases (PARPs 1-16) have emerged as major regulators of diverse cellular processes. PARPs can be subclassified based on their ability to catalyze poly-ADP-ribosylation (PARylation) or mono-ADP-ribosylation (MARylation). While much is